JANX

10.0802.04%
JD

Janeen Doyle

Chief Corporate & Business Development Officer

Ms. Janeen Doyle is Chief Corporate & Business Development Officer of Janux Therapeutics, Inc. from May 2025. She brings more years of broad and strategic experience spanning large pharmaceutical companies, mid-sized biotech and high-growth venture-backed enterprises to her role as Chief Corporate and Business Development Officer at Janux. Prior to joining Janux, She served as a Senior Partner and Senior Vice President of Corporate Partnerships and Program Development at Flagship Pioneering from June 2024 until May 2025. At Flagship, she was responsible for strategy and execution of collaborations between Flagship’s portfolio companies and global pharmaceutical and technology partners. Prior to Flagship, Janeen spent over several years at Bristol Myers Squibb and Celgene in a breadth of cross-functional positions of increasing responsibility, starting in areas of medical affairs and program leadership and most recently serving as Senior Vice President of Strategy & Business Development. In that role, she oversaw a portfolio of 300+ strategic collaborations and a broad equity investing portfolio, including serving as a board observer across investments. Her leadership encompassed partnerships from discovery through commercialization across multiple therapeutic areas. Previous to that, she held roles in clinical science and operations. She received a Bachelor of Science in biology from Moravian University and a Master of Business Administration from the University of Scranton.

Positions